CUTANEOUS T-CELL LYMPHOMA, RELAPSED

Clinical trials for CUTANEOUS T-CELL LYMPHOMA, RELAPSED explained in plain language.

Never miss a new study

Get alerted when new CUTANEOUS T-CELL LYMPHOMA, RELAPSED trials appear

Sign up with your email to follow new studies for CUTANEOUS T-CELL LYMPHOMA, RELAPSED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for Hard-to-Treat skin cancer: safer chemo combo enters trials

Disease control Not yet recruiting

This study tests a new combination of drugs (aclarubicin plus cyclophosphamide, vincristine, and prednisone, called CAOP) in 37 people aged 60+ with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare skin cancer. The goal is to find the safest dose and see if it shri…

Matched conditions: CUTANEOUS T-CELL LYMPHOMA, RELAPSED

Phase: PHASE1, PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control

Last updated May 07, 2026 18:41 UTC

CUTANEOUS T-CELL LYMPHOMA, RELAPSED

Get alerted when new CUTANEOUS T-CELL LYMPHOMA, RELAPSED trials appear

New hope for Hard-to-Treat skin cancer: safer chemo combo enters trials